- Title
- CAR T cell therapies for diffuse midline glioma
- Creator
- Thomas, Bryce C.; Staudt, Dilana E.; Douglas, Alicia M.; Monje, Michelle; Vitanza, Nicholas A.; Dun, Matthew D.
- Relation
- Trends Cancer Vol. 9, Issue 10, p. 791-804
- Publisher Link
- http://dx.doi.org/10.1016/j.trecan.2023.07.007
- Publisher
- Cell Press
- Resource Type
- journal article
- Date
- 2023
- Description
- Diffuse midline glioma (DMG) is a fatal pediatric cancer of the central nervous system (CNS). The location and infiltrative nature of DMG prevents surgical resection and the benefits of palliative radiotherapy are temporary; median overall survival (OS) is 9-11 months. The tumor immune microenvironment (TIME) is 'cold', and has a dominant immunosuppressive myeloid compartment with low levels of infiltrating lymphocytes and proinflammatory molecules. Because survival statistics have been stagnant for many decades, and therapies targeting the unique biology of DMG are urgently needed, this has prompted the clinical assessment of chimeric antigen receptor (CAR) T cell therapies in this setting. We highlight the current landscape of CAR T cell therapy for DMG, the role the TIME may play in the response, and strategies to overcome treatment obstacles.
- Subject
- diffuse midline glioma; chimeric antigen receptor T cell therapy; tumor immune microenvironment; CNS tumors; locoregional infusion
- Identifier
- http://hdl.handle.net/1959.13/1488179
- Identifier
- uon:52367
- Identifier
- ISSN:2405-8033
- Rights
- © 2023 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
- Language
- eng
- Full Text
- Reviewed
- Hits: 1366
- Visitors: 1493
- Downloads: 141
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 2 MB | Adobe Acrobat PDF | View Details Download |